Corvus Pharmaceuticals, Inc. Stock price
Equities
CRVS
US2210151005
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.78 USD | -0.56% | -3.78% | +1.14% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 87.29M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -45M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.12
x | P/E ratio 2025 * |
-2.83
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.43% |
Latest transcript on Corvus Pharmaceuticals, Inc.
1 day | -0.56% | ||
1 week | -3.78% | ||
Current month | -20.54% | ||
1 month | -24.58% | ||
3 months | +3.49% | ||
6 months | +22.76% | ||
Current year | +1.14% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Miller
CEO | Chief Executive Officer | 73 | 14-01-26 |
Leiv Lea
DFI | Director of Finance/CFO | 70 | 14-01-26 |
James Rosenbaum
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Miller
CEO | Chief Executive Officer | 73 | 14-01-26 |
Ian Clark
BRD | Director/Board Member | 62 | 17-01-02 |
Terry Gould
BRD | Director/Board Member | 67 | 14-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.78 | -0.56% | 273,600 |
24-03-27 | 1.79 | +1.70% | 161,298 |
24-03-26 | 1.76 | 0.00% | 302,463 |
24-03-25 | 1.76 | -1.68% | 277,924 |
24-03-22 | 1.79 | -2.72% | 324,851 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.14% | 87.78M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |